16 September 2023 in European Journal of Ophthalmology
Purpose: To recognize prognostic factors for better final visual acuity (VA) in patients presenting with submacular hemorrhage (SMH) secondary to exudative age-related macular degeneration . Methods: This retrospective study included patients who presented to a tertiary ophthalmology department between 2012 and 2019 with SMH and were treated by pars plana vitrectomy (PPV) or injection of tissue plasminogen activator (tPA) with pneumatic displacement. Baseline characteristics included demographic data, VA and optical coherence tomography (OCT) characteristics of the SMH. Patients were divided into groups by improvement of at least 2 lines in BCVA (best corrected visual acuity), and by having a final BCVA better than 20/200. Results: Forty-three eyes of 43 patients were included. Mean age was 86.72 ± 7.18. Prognostic factors for final VA better than 20/200 included better VA at presentation (1.25 vs 1.90 logMAR, p < 0.001), smaller area of SMH in the infra-red image (19.47 mm 2 vs 38.45 mm 2 , p = 0.024), and lower height of SMH as measured by OCT (713.5 µm vs 962.5 µm, p = 0.03). Third of the patients improved in ≥2 lines from presentation, all in the group of the pneumatic and TPA displacement. Conclusion: Smaller SMHs with good VA at presentation have a better chance for improvement and result in a better final VA. These patients may benefit the most from pneumatic displacement of the SMH with intravitreal tPA and gas.
1 July 2026 in Ophthalmology Retina
4 June 2025 in European Journal of Ophthalmology
Purpose: To examine and report the long-term natural history of benign essential blepharospasm (BEB) and hemifacial spasm (HFS) patients treated in the botulinum toxin facial spasm clinic and identify and examine any cases of resolution. Methods: This is a retrospective cohort study of all patients who were or still are being treated with Botulinum toxin injections for BEB or HFS from University Hospitals Sussex (UHS), UK and Rabin Medical Center (RMC), Israel, between 2000 and 2024. Patients who ceased treatment were examined in greater detail to identify the reasons for stopping treatment and the likelihood of spontaneous resolution of spasms. Results: The study included 233 patients. The median age at diagnosis was 65 (IQR = 17) years, and 141 (60.5%) were female. 162 (69.5%) patients had BEB and 71 (30.5%) HFS. Of the HFS patients, 40 (56.4%) had right-side spasms. The overall median follow-up time was 52 months (IQR = 79.5). The patients were divided into four groups based on their treatment status. Group 1 (57.9%) – patients who were still receiving Botulinum toxin treatment, or had received it until they died, Group 2 (5.2%) – patients with symptom resolution, who did not require further treatment, Group 3 (30%) – patients who discontinued treatment with no clinical improvement, and Group 4 (6.9%) – lost to follow-up. Conclusions: Facial spasms are usually a lifelong condition. However, contrary to general thinking, there is a 5% chance of long-term spasms resolving, although predictors for resolution remain elusive.